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Abstract
Background: Many of the posttraumatic stress disorder (PTSD) treatment guidelines recognize the use of selective
serotonin reuptake inhibitors as first-line pharmacological treatment. In Japan, there were no published studies
investigating the effectiveness and safety of sertraline for PTSD in a clinical setting.
Methods: We conducted a retrospective medical chart review of the dosage, effectiveness, and safety of sertraline
for the PTSD treatment in Japan. Data were collected from medical charts of patients of PTSD, caused by various
types of trauma, who were treated with sertraline between July 2006 and October 2012 during their regular clinical
practice. To evaluate the effectiveness, the investigators retrospectively assessed the severity and improvement of
the symptoms using the Clinical Global Impressions − Severity and the Clinical Global Impressions − Improvement.
Results: The study population was 122 Japanese patients aged ≥18 years with a diagnosis of PTSD who were
treated with sertraline (median duration, 10.6 months). Doses ranged from 12.5 to 150 mg/day, mostly 25 and
50 mg/day. The median duration of observation was 10.8 months. Out of those, 50% of patients were regarded as
responders by using the Clinical Global Impressions - Improvement at the end of sertraline treatment or the last
observation. Two-thirds (65.6%) of patients improved in the severity of PTSD, as assessed by Clinical Global Impressions -
Severity, whereas 32.8% showed no change, and 1.6% worsened. Subgroups analyses and logistic regression analyses
suggested that the type of traumatic events was the factor with the highest influence on the response rate. The adverse
events in this chart review were consistent with the known safety profile of sertraline. There were no reports of serious or
severe adverse events considered to be related to sertraline.
Conclusions: Our study suggested the effectiveness of sertraline for the treatment of PTSD in a Japanese clinical setting,
and the obtained safety profile was consistent with the generally known safety profile of sertraline.
Trial registration: ClinicalTrials.gov (Identification No. NCT01607593). Registered May 21, 2012.
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Background
Posttraumatic stress disorder (PTSD) is a psychiatric
disorder caused by various traumatic events (e.g., disas-
ters, violence, sexual violence, severe accidents, battles,
and child abuse). PTSD is associated with significant
symptom-related stress and functional impairment.
PTSD shows a high degree of co-morbidity of other
anxiety, depression, substance use disorders and suicide
[1–3]. Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition (DSM-IV) requires three different
types of symptoms to diagnose PTSD; re-experiencing
symptoms, avoidance and numbing symptoms, and
arousal symptoms [4]. DSM-5 has been released in 2013
and the three clusters of symptoms required in DSM-IV
are divided into four clusters; intrusion, avoidance, nega-
tive alterations in cognitions and mood, and alterations
in arousal and reactivity [5].
Established treatments for PTSD include pharmaco-
logical treatments such as antidepressants, and special-
ized psychologic treatments such as cognitive behavior
therapy (CBT) and eye movement desensitization and
reprocessing (EMDR) [6]. Pharmacological therapy,
though effect size for psychological therapy is reported
much larger, has been shown its benefit. Several evi-
dences also show that combining pharmacological treat-
ment and CBT enhances the efficacy of either treatment
alone [7]. Most treatment guidelines recognaize certain
benefit of pharmacological approach and recommend
the use of SSRIs as the first-line drug for PTSD based
on evidence from randomized placebo-controlled trials
[8]. Pharmacological treatment also has its advantages in
patient’s access. It is widely conducted as it can be pro-
vided not only by specialists but also by general practi-
tioners, whereas only a limited number of professionals
can conduct specialized psychological treatments. Thus,
it is expected that pharmacotherapy is practical and con-
venient, especially in case of the number of PTSD
patients may increase suddenly and locally, such as
sudden huge disasters.
Sertraline and paroxetine are currently only approved
drugs for the treatment of PTSD in the United States
and EU countries based on double-blined placebo-
controlled randomized clinical trials. These trials dem-
onstrated superiority of the drug to placebo in change
from baseline in Clinician Administrated PTSD scale for
DSM-IV (CAPS-2) total score [9–13]. To the best of our
knowledge, sertraline is the only approved drug that
have been demonstrated relapse-prevention effect for
PTSD in double-blind placebo-conrolled study [14].
In Japan, sertraline and paroxetine were first approved
for the treatment of depression and some anxiety disor-
ders, but not for PTSD, at the time of study initiation.
Despite this situation, several studies [15–17] and a mul-
ticenter retrospective survey [18] revealed that SSRIs,
including sertraline, were used for the treatment of
PTSD in Japanese patients. A study from Korea [19], a
neighboring country, also showed the effectiveness of
sertraline among their veterans. However, there were no
published studies investigating actual prescription of ser-
traline, and its effectiveness and safety for PTSD caused
by various types of trauma in Japan. According to the
studies in Japan and South Korea, there seem to be not
large differences on the efficacy and safety profile of ser-
traline in patients with PTSD between western and east-
ern countries. However, because the approved dose
range in Japan (25–100 mg/day) is lower than those in
other countries (e.g. 50–200 mg/day in the US), it is
necessary to examine the efficacy and safety of sertra-
line in Japanese patients with PTSD separately. This
retrospective study was conducted to investigate the
dosage regimens, effectiveness, and safety of sertraline




Following approvals from the institutional ethical
review boards of Tokyo Women’s Medical University,
Kurume University, Hyogo Institute for Traumatic
Stress and National Defense Medical College, we con-
ducted a retrospective chart review of patients who
had been treated with sertraline as part of their regu-
lar clinical practice, from August to October 2012, at
four medical institutions that provide specialized care
for PTSD patients in Japan. We investigated the
dosage, effectiveness, and safety of sertraline in the
treatment of PTSD. This study is presented in part in
the clinical trial registry located at ClinicalTrials.gov
(Identification No. NCT01607593).
Study population selection
The study was conducted in the following four medical
institutions in Japan; Institute of Women’s Health,
Tokyo Women’s Medical University; Department of
Neuropsychiatry, Kurume University; Hyogo Institute
for Traumatic Stress; and Department of Psychiatry,
National Defense Medical College Hospital. Inclusion
criteria included (1) male and female outpatients aged
18 years or older; (2) patients who had been diagnosed
PTSD by investigators using diagnosis criteria from
DSM-IV before the investigators initiated to prescribe
sertraline; and (3) patients who had started treatment
with sertraline between July 2006 (the start of sertraline
marketing in Japan) and October 2012 (the initiation of
data entry at the institutions). Exclusion criteria were
not set for this study.
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Assessments
All assessments on each subject were performed by the
investigator who had diagnosed the patient. Patient char-
acteristics (e.g., age, gender, date of PTSD diagnosis,
traumatic events, and medical history), duration and
dosage of treatment, treatment status with sertraline
(i.e., “completed,” “discontinued,” “continuing”), and
concomitant treatments including augumentation treat-
ments (antipsychotics and psychotherapies added to
study treatment) were recorded in the Case Report
Form. To assess the severity and improvement of PTSD
symptoms, the Clinical Global Impressions – Severity
(CGI-S) and Clinical Global Impressions – Improvement
(CGI-I) ratings [20] were retrospectively determined by
investigators based on the medical records. CGI-S was
rated at the initiation of sertraline treatment (baseline)
and at the end of treatment or the last observation; 1:
normal, not at all ill, 2: borderline, mentally ill, 3: mildly
ill, 4; moderatery ill, 5: markedly ill, 6: severery ill, 7:
among the most extremely ill. CGI-I was rated at the
end of treatment or the last observation compared to
baseline; 1: very much improved, 2: much improved, 3:
minimally improbed, 4: no change, 5: minimally worse,
6: much worse, 7: very much worse. Factors that could
influence the effectiveness (e.g., treatment with sertraline
for less than 4 weeks, poor medication compliance, and
life events such as court litigation) were recorded. All
adverse events in the medical charts that were reported
during the treatment with sertraline were also recorded.
The severity and causal relationship of adverse events
with sertraline were determined by the investigators. If
the investigator’s final determination of causality is un-
known and the investigator does not know whether ser-
traline caused the event, then the event were handled as
related to sertraline for reporting purposes. If the inves-
tigator’s causality assessment is unknown but not related
to sertraline this should be clearly documented in the
Case Report Form. Discontinuation syndrome, self-injury
or violence towards others and activation syndrome, are
pre-defined as events concerned during treatment SSRIs
and focused of this investigation.
Statistical analyses
The CGI-I and CGI-S ratings were summarized for the
full analysis set (FAS), which was defined as all patients
with available scores for either CGI-I or CGI-S. Patients
who were rated as “very much improved” or “much im-
proved” in the CGI-I rating were defined as responders,
whereas the remaining patients were regarded as non-
responders. The proportion of responders was referred
to as the response rate. The CGI-I ratings were tabu-
lated, and the CGI-S ratings were summarized by cross
tabulation of baseline and endpoint data. These analyses
of effectiveness were also performed for a subgroup of
patients that excluded those with factors that may po-
tentially influence effectiveness. Adverse events were
summarized in the safety analysis set, which was defined
as all patients included in this chart review. Adverse
events were coded by the Medical Dictionary for Regulatory
Activities (MedDRA, version 15.1).
To explore patient characteristics that may influence
the treatment of PTSD, subgroup analyses of dependent
variables (the CGI-I rating, augmentation of treatment
and dosage of sertraline) were performed on independ-
ent variables defined prior to initiation of data collection:
age, duration of disease, concurrent psychiatric disease,
traumatic events, and baseline CGI-S. Logistic regression
analyses were also performed as pre-defined with
responder (vs. non-responder) or at least one treatment
augmentation (vs. no treatment augmentation) as the
depedent variable, and age, duration of disease, concur-
rent psychiatric diseases at baseline, traumatic events,
and baseline CGI-S as independent variables.
Results
Patient characteristics
A total of 122 patients were included in the study.
Among the 122 patients, 119 (approximately 98%) were
females and three were males (Table 1). The mean age
was 35.6 years, and approximately 80% of the patients
were under the age of 45. The median duration of PTSD
was 2.0 months, ranging from −3.9 months to
Table 1 Demographic and clinical characteristics
Characteristics Sertraline
N = 122
Age (year), mean (SD) 35.6 (10.4)
Gender distribution
Male, n (%) 3 (2.5)
Female, n (%) 119 (97.5)
Duration of PTSD (month), mean (range) 2.0 (−3.9 to
74.3)




Witnessing violence or death 8
Captivity 6





Patient with co-morbid psychiatric diseases at baseline,
n (%)
93 (76.2)
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74.3 months (the minimum value is a negative figure,
because sertraline was prescribed to one patient with
suspected PTSD, and the diagnosis was subsequently
confirmed). Traumatic events leading to PTSD were
physical assault (74 patients), sexual assault (43 patients),
child abuse (14 patients), witnessing violence or death
(eight patients), captivity (six patients), motor vehicle
accident, other accident (five patients each), natural dis-
aster (two patients), fire (one patient) and other (six pa-
tients). Ninety-three patients (76.2%) had co-morbid
psychiatric disorders at baseline, the most common
being depression (53.3%) and dysthymic disorder (8.2%).
The median duration of observation was 10.8 months
(range 0 – 63 months). Of the 122 patients, 60 (49.2%)
discontinued the treatment. The main reasons for dis-
continuation were insufficient clinical response (16 pa-
tients, 13.1%) and adverse events considered related to
sertraline (13 patients, 10.7%); another 25 patients
(20.5%) were lost to follow-up.
The median duration of treatment with sertraline was
10.6 months (range 0 – 63 months). The dose ranged
from 12.5 to 150 mg/day, and the most frequently used
doses were 25 and 50 mg/day (43 patients [35.2%] and
35 patients [28.7%], respectively). Only two patients
received doses exceeding 100 mg/day (125 and 150 mg/
day in one patient each). Concomitant drug and non-drug
treatments were used in 121 patients (99.2%) and 16
patients (13.1%), respectively.
Effectiveness
All 122 patients were included in the FAS. The CGI-I
ratings were “very much improved” in 23 patients
(18.9%), “much improved” in 38 patients (31.1%), “min-
imally improved” in 25 patients (20.5%), “no change” in
32 patients (26.2%), and “minimally worse” in four
patients (3.3%). The response rate was 50.0% (61
responders). In the subgroup of patients excluding those
with factors potentially influencing effectiveness (60 pa-
tients), the response rate was 60.0% (36 responders), and
only one patient was rated as “minimally worse.”
Table 2 shows a shift table of the CGI-S ratings from
baseline to the end of treatment or the last observation
(bold face indicated the number of patients who showed
improvement in severity from baseline). The CGI-S rat-
ings at baseline were “mild” in 16 patients (13.1%),
“moderate” in 68 patients (55.7%), “marked” in 17 pa-
tients (13.9%), “severe” in 20 patients (16.4%), and “most
severe” in one patient (0.8%). The CGI-S rating at the
end of treatment or the last observation showed an over-
all improvement from baseline, with improvement in
severity observed in 80 patients (65.6%), no change in 40
patients (32.8%), and worsening in two patients (1.6%).
In the subgroup of patients that excluded those with
factors potentially influencing effectiveness, improve-
ment in severity similar to that seen in the FAS were
observed, and there were no patients who exhibited
worsening of severity from the baseline level.
Table 2 Clinical Grobal Impressions-Severity at baseline and the end of treatment
Baseline N = 122 The end of sertraline treatment or the last observation N = 122
Normal Borderline Mild Moderate Marked Severe Most severe Not assessed
13 (10.7) 19 (15.6) 40 (32.8) 40 (32.8) 4 (3.3) 5 (4.1) 1 (0.8) 0
Normal 0 0 0 0 0 0 0 0 0
Borderline 0 0 0 0 0 0 0 0 0
Mild 16 (13.1) 3 (2.5) 4 (3.3) 7 (5.7) 2 (1.6) 0 0 0 0
Moderate 68 (55.7) 6 (4.9) 11 (9.0) 26 (21.3) 25 (20.5) 0 0 0 0
Marked 17 (13.9) 2 (1.6) 1 (0.8) 4 (3.3) 8 (6.6) 2 (1.6) 0 0 0
Severe 20 (16.4) 2 (1.6) 3 (2.5) 3 (2.5) 5 (4.1) 2 (1.6) 5 (4.1) 0 0
Most severe 1 (0.8) 0 0 0 0 0 0 1 (0.8) 0
Not assessed 0 0 0 0 0 0 0 0 0
Values represent the number (%) of patients
Bold = patients who showed improvement in severity from baseline
Normal, normal, not at all ill, Borderline borderline mentally ill, Mild mildly ill, Moderate moderately ill, Marked markedly ill, Severe severely ill, Most severe most
severely ill








Abdominal discomfort 5 (4.1) 3 (2.5)
Abdominal pain upper 5 (4.1) 2 (1.6)
Diarrhoea 7 (5.7) 4 (3.3)
Dry mouth 7 (5.7) 6 (4.9)
Nausea 12 (9.8) 11 (9.0)
Intentional overdose 5 (4.1) 0
Headache 12 (9.8) 8 (6.6)
Somnolence 11 (9.0) 10 (8.2)
Values represent the number (%) of patients
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Safety
A total of 73 patients (59.8%) experienced a total of 187
adverse events regardless of causality, and 54 (44.3%) ex-
perienced a total of 100 adverse events considered to be
related to sertraline. Table 3 represents the adverse
events observed in five or more patients. The most com-
monly observed adverse events (≥10 patients) were nau-
sea and headache (12 patients, 9.8%, each) and
somnolence (11 patients, 9.0%), most of which were con-
sidered to be treatment-related. Sixteen patients (13.1%)
discontinued sertraline and eight patients (6.6%) received
a reduced dose or temporarily suspended sertraline due
to adverse events, most of which were considered
treatment-related. Discontinuation syndrome, self-injury
or violence towards others, and activation syndrome,
which are events of concern during treatment with
SSRIs, were observed in one patient (0.8%), nine patients
(7.4%), and one patient (0.8%), respectively. The
treatment-related adverse events that caused discontinu-
ation or dose reduction in multiple patients were nausea
(five patients), somnolence (three patients), as well as
headache and dry mouth (two patients each). Seven pa-
tients (5.7%) reported serious adverse events (acute mye-
loid leukaemia; pituitary tumour; suicide attempt;
intentional overdose; intentional self-injury: ovarian
neoplasm; hallucination, thinking abnormal); and two
patients (1.6%) experienced severe adverse events (ovarian
neoplasm and acute myeloid leukaemia), but none of these
serious or severe adverse events were considered to be
related to sertraline.
Fig. 1 Propotion of responder in Clinical Grobal Impression-Improvement Ratings by patient characteristics. Responders: patients who were rated
as “very much improved” or “much improved” in the CGI-I rating. Values in the bar chart represent the proportion (%) of patients. Age-subgroups
were divided by the quartiles. No sexual assault: patients experienced traumatic events including physical assault, but no sexual assault. No physical assault:
patients experienced traumatic events including sexual assault, but no physical assault
Table 4 Logistic regression analysis: responder vs. non-responder
Factor d.f. Chi-Square
statistic
p-value Odds ratio estimates
Point estimate 95% C.I.
Age 1 1.75 0.186 0.97 0.94 1.01
Duration of disease 1 0.26 0.610 0.99 0.97 1.02
Baseline CGI-S 1 0.43 0.510 1.15 0.76 1.76
Concurrent psychiatric disease at baseline 2 1.61 0.447 Depression or Dysthymic disorder vs. None 1.74 0.64 4.74
Other Psychiatric disease vs. None 2.23 0.58 8.55
Traumatic events 3 7.43 0.060 Both Physical and sexual assault vs. Neither 0.12 0.03 0.56
No sexual assault vs. Neither 0.38 0.12 1.20
No physical assault vs. Neither 0.30 0.08 1.12
d.f. Degree of freedom, C.I. Confidence interval
Responders: patients who were rated as “very much improved” or “much improved” in the CGI-I rating
No sexual assault: patients experienced traumatic events including physical assault, but no sexual assault
No physical assault: patients experienced traumatic events including sexual assault, but no physical assault
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Investigation of factors potentially influencing the treatment
outcome of PTSD
Subgroup analyses of the CGI-I ratings by patient char-
acteristics suggested that PTSD symptoms improved to
a lesser degree in patients older than 43 years, those
with mild severity at baseline (CGI-S score of 3), and
those who had experienced both physical and sexual as-
sault as trauma (Fig. 1). Logistic regression analyses indi-
cated that the type of traumatic events was the factor
with the highest influence on the response rate among
the explanatory variables we selected (Table 4). In par-
ticular, the response rate in patients who had experi-
enced both physical and sexual assault was much lower
than in those who experienced neither (odds ratio, 0.12;
95% confidence interval, 0.025 to 0.556).
Subgroup analyses also suggested that augmentation of
treatment (prolonged exposure therapy, antipsychotics
or mood stabilizer) was more likely in patients who had
experienced sexual assault as trauma (Table 5), and that
a higher dose was more likely to be administered to pa-
tients with severe symptoms at baseline (CGI-S score of
≥5) and those who experienced both physical and sexual
assault as trauma (Figs. 2 and 3). Augmentation of treat-
ment was most highly affected by the type of the
traumatic events among the five explanatory variables
(Table 6). In particular, there was a much higher possi-
bility of augmentation of treatment in patients who ex-
perienced traumatic events including sexual assault, but
not physical assault than in those who experienced nei-
ther (odds ratio, 3.80; 95% confidence interval, 1.026 to
14.056).
Discussion
Our study indicated that sertraline was well-tolerated,
and the PTSD symptoms, according to the CGI-I rating,
improved during sertraline treatment. In Japan, the
approved sertraline dose for major depressive disorder
and panic disorder was lower dose than that in the
United States (25–100 mg/day vs. 50–200 mg/day), and
most of the study patients were treated within this dose.
Nonetheless, our findings were consistent with previous
American findings [9, 10]. Our study data were collected
from medical charts of all PTSD patients treated with
sertraline who visited the four specialized medical insti-
tutions in Japan where they received regular clinical
practice. This mminimized the selection bias of patients.
The results are also considered to reflect the usage of
sertraline in the regular clinical practice and might be
extrapolated to similar medical institutions in Japan.
Table 5 Augmentation of treatment by traumatic event






Neither physical nor sexual assault
(n = 22)
Two treatments 5 (29.4) 7 (12.3) 4 (15.4) 4 (18.2)
One treatment 5 (29.4) 13 (22.8) 16 (61.5) 6 (27.3)
None 7 (41.2) 37 (64.9) 6 (23.1) 12 (54.5)
Treatment type
PE therapy 2 (11.8) 4 (7.0) 4 (15.4) 2 (9.1)
Antipsychotics 10 (58.8) 17 (29.8) 16 (61.5) 8 (36.4)
Mood stabilizer 3 (17.6) 6 (10.5) 4 (15.4) 4 (18.2)
PE prolonged exposure therapy
Fig. 2 Dosage (mg/day) by baseline CGI-S score. Values in the bar chart represent the number of patients
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The majority of our study patients were female
(97.5%), so there were not enough data to examine gen-
der differences within our study group. An American
community study had suggested that females were ap-
proximately twice as likely as males to develop PTSD
(lifetime prevalence; females, 10.4% vs. males, 5.0%) [21].
A similar trend was observed among the Japanese popu-
lation (1.3% among females and 0.6% among males) [22].
These studies indicated that females had a higher preva-
lence of PTSD than males, whereas meta-analysis of
pharmacotherapy for PTSD indicated that gender did
not affect treatment outcome [8]. There were also no
gender-related differences in treatment outcomes among
depressed patients who were treated with sertraline [23].
Our study might suggest that PTSD can be treated with
sertraline regardless of gender, but further studies will be
needed to validate this theory.
Our analysis showed a tendency for lower CGI-I
response rate among patients who experienced both
physical and sexual assault as their traumatic events.
Although 70.6% of patients who experienced both events
showed improvement, the response rate in this subgroup
was 29.4%, whereas it was 68.2% in patients who experi-
enced neither physical nor sexual assault. Logistic
regression analysis also showed a similar trend. In
addition, a higher dose of sertraline was observed in a
higher portion of patients with physical and sexual trau-
matic events. A marked difference in the usage of anti-
psychotic drugs between the different trauma types were
shown; patients who experienced sexual assault were
more likely to have add-on treatment with antipsychotic
drugs regardless of whether they had experienced phys-
ical assault compared to those without sexual assault.




Fig. 3 Dosage (mg/day) by traumatic event. Values in the bar chart represent the number of patients. Both: patients experienced traumatic events
both physical assault and sexual assault. No sexual: patients experienced traumatic events including physical assault, but no sexual assault. No physical:
patients experienced traumatic events including sexual assault, but no physical assault. Neither: patients experienced traumatic events neither physical
assault or sexual assault







Point estimate 95% C.I.
Age 1 0.40 0.526 1.01 0.97 1.05
Duration of disease 1 0.04 0.836 1.00 0.98 1.03
Baseline CGI-S 1 0.22 0.638 1.11 0.73 1.69
Concurrent psychiatric disease at baseline 2 0.46 0.793 Depression or Dysthymic disorder vs. None 1.35 0.49 3.76
Other Psychiatric disease vs. None 1.54 0.40 5.94
Traumatic events 3 11.54 0.009 Both Physical and sexual assault vs. Neither 1.43 0.35 5.75
No sexual assault vs. Neither 0.57 0.19 1.64
No physical assault vs. Neither 3.80 1.03 14.06
d.f. Degree of freedom, C.I. Confidence interval
No sexual assault: patients experienced traumatic events including physical assault, but no sexual assault
No physical assault: patients experienced traumatic events including sexual assault, but no physical assault
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severity/chronicity, which may depend on traumatic
experiences.
The present study collected type of traumatic events
leading to PTSD as background but did not collect data
on number of traumatic events experienced. We were
thus not able to investigate differences in treatment out-
come and predicitive impact between multiple and single
events of trauma. However, the observation that patients
with physical and sexual trauma are more likely to have
treatment-resistant PTSD suggests that the diagnosis
and identification of the types of traumatic events are
important to determine the treatment strategy. On the
other hand, a higher response rate in patients who expe-
rienced neither physical nor sexual assault suggests that
pharmacological treatment may provide greater benefit
to patients with single trauma. A population-based,
cross-national chart review suggested that patients with
PTSD associated with multiple traumatic events or
repeated exposure to the same traumatic event had
severer morbidity and impairment compared to those
patients with PTSD caused by a single traumatic event
[24]. Further research is required to examine the treat-
ment outcome by type or number of traumatic events.
This study was a retrospective study and it includes
some limitations. First, the nature and the design of the
investigation limited the data collection including assess-
ments by rating scales and there still is a possibility of
residual confounding and inherent bias in the data col-
lected. Second, as sertraline dose had been adjusted by
the each patient’s symptoms and/or conditions during
PTSD treatment, therefore we could not examine dose
response relationship of efficacy among Japanese PTSD
patient. Sertraline dose is considered as one of the re-
sponse variables and We are also not able to include the
dosing information in the logistic regression model.
Third, the number of patients was variable among the
four institutions and this may cause imbalance among
the institutions in patient characteristics such as gender.
Finally, a relatively large percentage of patients discon-
tinued sertraline, although this trend has been seen in
other surveys conducted in Japan [18, 25]. Given these
limitations, our findings indicated that the symptoms of
PTSD improved during treatment with sertraline with-
out additional safety concerns. Further prospective con-
trolled studies are needed to confirm our findings.
Conclusions
The results of this study suggested the effectiveness of
sertraline for the treatment of PTSD, and the obtained
safety profile was consistent with the generally known
safety profile of sertraline.
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